These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1088246)

  • 21. Development of folates and folic acid antagonists in cancer chemotherapy.
    NCI Monogr; 1987; (5):1-223. PubMed ID: 3431587
    [No Abstract]   [Full Text] [Related]  

  • 22. Biochemical and pharmacologic rationale for high-dose methotrexate.
    Jolivet J
    NCI Monogr; 1987; (5):61-5. PubMed ID: 2448656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.
    Sadée W
    Ther Drug Monit; 1980; 2(2):177-85. PubMed ID: 6762711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A portable pump ("conjector") for regional perfusion cancer chemotherapy.
    Barkin M; Cowan CR; MacDonald JA; Mahoney LJ
    Can Med Assoc J; 1966 Nov; 95(21):1087-9. PubMed ID: 5297053
    [No Abstract]   [Full Text] [Related]  

  • 26. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
    Diddens H; Niethammer D; Jackson RC
    Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Some considerations of folic acid antagonists.
    Scott CW
    Ala J Med Sci; 1971 Jan; 8(1):99-106. PubMed ID: 5578506
    [No Abstract]   [Full Text] [Related]  

  • 29. [Correct use of methotrexate].
    Verduijn MM; van den Bemt BJ; Dijkmans BA; van der Waal RI; Horikx A
    Ned Tijdschr Geneeskd; 2009; 153():A696. PubMed ID: 19785852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of calcium folinate in the management of accidental methotrexate ingestion in two dogs.
    Lewis DH; Barfield DM; Humm KR; Goggs RA
    J Am Vet Med Assoc; 2010 Dec; 237(12):1450-4. PubMed ID: 21155685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study.
    Ettinger DS; Stanley KE; Nystrom JS
    Cancer Treat Rep; 1980; 64(10-11):1017-21. PubMed ID: 6970075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of diamino-dichlorophenyl-methylpyrimidine (DDMP) with folinic acid (CF) protection and rescue.
    Alberto P; Brugarolas A; Hansen HH; Cavalli F; Klepp O; Renard J
    Eur J Cancer (1965); 1980 Sep; 16(9):1243-9. PubMed ID: 6971756
    [No Abstract]   [Full Text] [Related]  

  • 34. Monitoring of methotrexate and reduced folates in the cerebrospinal fluid of cancer patients.
    Vezmar S; Bode U; Jaehde U
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):582-3. PubMed ID: 12503823
    [No Abstract]   [Full Text] [Related]  

  • 35. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
    Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
    Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
    Galivan J; Nimec Z; Rhee M
    Cancer Res; 1987 Oct; 47(20):5256-60. PubMed ID: 2958130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards selectivity in cancer chemotherapy: a biochemical overview.
    Harrap KR
    Adv Enzyme Regul; 1978; 17():457-78. PubMed ID: 393091
    [No Abstract]   [Full Text] [Related]  

  • 39. Approaches to selectivity in cancer chemotherapy.
    Bertino JR
    Adv Pathobiol; 1976; 2():65-9. PubMed ID: 1088246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
    Goldman ID; Matherly LH
    NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.